Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C news

Show

From To
Improving access to, and completion of, hepatitis C treatment

Treating hepatitis C infection is an effective and cost-effective way to substantially reduce prevalence, especially in areas where it is high. Compliance with the new treatment is easier and can be further improved by well-planned support for patients. .

Published
11 hours ago
From
Public Health England
Medicines Patent Pool At 5 Years: Promises Kept, Changes Ahead – An Interview With Greg Perry

The Medicines Patent Pool in Geneva is celebrating five years of existence this month. MPP Executive Director Greg Perry sat down with Intellectual Property Watch Catherine Saez to describe progress made since its inception, the success of its licensing agreement model, and plans for the future, including a possible extension to other diseases such as tuberculosis and hepatitis C.

Published
12 hours ago
From
Intellectual Property Watch
Daclatasvir plus sofosbuvir cures HCV for most people with HIV and HCV co-infection in French compassionate use programme

Interferon-free treatment using daclatasvir (Daklinza) and sofosbuvir (Sovaldi), with or without ribavirin, was well-tolerated and produced sustained virological response rates of 95-100% for people with HIV and

Published
03 August 2015
By
Liz Highleyman
NICE issues appraisal consultation documents for three new hepatitis C therapies

The National Institute for Clinical Excellence (NICE) has today issued appraisal consultation documents for three new hepatitis C therapies; ledipasvir-sofosbuvir (Harvoni), daclatasvir (Daklinza, and ombitasvir/paritaprevir/ritonavir (with or without dasabuvir).

Published
30 July 2015
From
Hepatitis C Trust
Gilead Profit Tops Estimates as Hepatitis C Drug Sales Surge

Gilead Sciences Inc., maker of the hepatitis C drugs Sovaldi and Harvoni, posted second-quarter profit that topped analysts’ estimates as revenue surged. Gilead raised its sales forecast for the year.

Published
30 July 2015
From
Bloomberg
Merck Targets Toughest Cases to Gain Hepatitis C Foothold

Merck & Co. plans to target hard-to-treat hepatitis C patients with its cure for the liver ailment rather than compete for market share by drastically undercutting the price of Gilead Sciences Inc.'s $1,000-a-day treatment.

Published
29 July 2015
From
Bloomberg
Georgia sets sights on eliminating hepatitis C

A combination of strong political will, public support and experience gained in HIV prevention and control led to this new programme. The Ministry of Labour, Health and Social Affairs is working with a pharmaceutical manufacturer to provide an initial 5000 courses of DAAs as the first part of the programme, followed by 20 000 treatment courses annually free of charge.

Published
27 July 2015
From
WHO Europe
Viral hepatitis – 400 deaths a day in the WHO European Region could be prevented

Over 13 million people in the WHO European Region are living with chronic hepatitis B infection and over 15 million with chronic hepatitis C infection. Two-thirds of those infected are in eastern Europe and Central Asia. Hepatitis B and C infections lead to 400 deaths in the Region every day.

Published
27 July 2015
From
WHO Europe
FDA OK’s BMS Daklinza (Daclatasvir) to Treat Hep C Genotype 3

The FDA has approved BMS's Daklinza (daclatasvir) to be used with Gilead Sciences’ Sovaldi (sofosbuvir) to treat genotype 3 of hepatitis C.

Published
27 July 2015
From
AIDSMeds
FDA approves Technivie for treatment of chronic hepatitis C genotype 4

The U.S. Food and Drug Administration today approved Technivie (ombitasvir, paritaprevir and ritonavir) for use in combination with ribavirin for the treatment of hepatitis C virus (HCV) genotype 4 infections in patients without scarring and poor liver function (cirrhosis).

Published
27 July 2015
From
FDA
← First12345...131Next →

Filter by country